Soligenix (NASDAQ:SNGX) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02, Fidelity Earnings reports. The firm had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $1.40 million. Soligenix had a negative return on equity of 125.42% and a negative net margin of 173.58%.
SNGX stock remained flat at $$1.05 during trading on Friday. The company had a trading volume of 1,278 shares, compared to its average volume of 237,227. The stock has a market cap of $20.56 million, a price-to-earnings ratio of -1.54 and a beta of 1.16. Soligenix has a 1 year low of $0.65 and a 1 year high of $2.20. The company has a fifty day simple moving average of $1.03 and a 200-day simple moving average of $0.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.20 and a current ratio of 2.20.
SNGX has been the topic of several recent research reports. Maxim Group restated a “buy” rating and issued a $4.00 price target on shares of Soligenix in a research report on Thursday, May 16th. ValuEngine upgraded Soligenix from a “sell” rating to a “hold” rating in a research report on Thursday, July 18th.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Read More: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.